<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00323960</url>
  </required_header>
  <id_info>
    <org_study_id>IGG-PRINTO-002</org_study_id>
    <secondary_id>AIFA</secondary_id>
    <secondary_id>Myositis Association</secondary_id>
    <nct_id>NCT00323960</nct_id>
  </id_info>
  <brief_title>Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis</brief_title>
  <acronym>PRINTOJDMTR</acronym>
  <official_title>Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Giannina Gaslini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pediatric Rheumatology International Trials Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Giannina Gaslini</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 5-year project, involving 185 partners from 46 countries ((110 in 21 European Union&#xD;
      (EU) States and 75 in 25 extra-EU States)), with a randomised clinical trials (RCT) in&#xD;
      juvenile dermatomyositis (JDM): 5-year phase III single-blind, RCT in children with newly&#xD;
      diagnosed JDM: prednisone (PDN) versus PDN plus methotrexate (MTX) versus PDN plus&#xD;
      Cyclosporine A. The trial is aimed to find out the treatment regimen associated with the&#xD;
      lowest occurrence of flare and the lowest drug related toxicity&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scientific objectives: The proposed project is aimed to improve treatment approaches for&#xD;
      rare, severe and disabling paediatric rheumatic diseases (PRD). This goal will be achieved by&#xD;
      the Paediatric Rheumatology International Trials Organisation (PRINTO) an international&#xD;
      network whose main function is to provide a scientific base for current PRD treatments for&#xD;
      which no evidence based data exist in the literature, and for drugs for which there is no&#xD;
      support from industries.&#xD;
&#xD;
      This is a 5-year project, involving 46 countries (110 in 21 EU States and 75 in 25 extra-EU&#xD;
      States), with a randomised clinical trials (RCT) in juvenile dermatomyositis (JDM): 5-year&#xD;
      phase III single-blind, RCT in children with newly diagnosed JDM: prednisone (PDN) versus PDN&#xD;
      plus methotrexate (MTX) versus PDN plus Cyclosporine A (CsA). The trial is aimed to find out&#xD;
      the treatment regimen associated with the lowest occurrence of flare and the lowest drug&#xD;
      related toxicity. The retention on treatment will be used as main measure of effectiveness.&#xD;
&#xD;
      Methodology: The present protocol is the natural follow up of previous work conducted by&#xD;
      PRINTO. In particular the RCT foreseen in this protocol is modelled after the successful&#xD;
      completion of an early phase trial with MTX in juvenile idiopathic arthritis, and will use&#xD;
      validated JDM outcome measures for the evaluation of response to therapy.&#xD;
&#xD;
      It is the basic premise of this protocol that, without i) the involvement of the&#xD;
      international paediatric rheumatology community, ii) the innovative type of mechanism&#xD;
      described herein, these studies would never be conducted.&#xD;
&#xD;
      Objectives. The goals of the current protocol is therefore the natural follow-up of the&#xD;
      objectives achieved with the previous grants and, in particular, of projects designed to&#xD;
      discern new models for the successful conduct of clinical trials in children with rare&#xD;
      diseases, and to develop standardized and validated measures for the evaluation of response&#xD;
      to therapy in JDM.&#xD;
&#xD;
      The proposed trial in JDM (prednisone [PDN] versus PDN plus methotrexate [MTX] versus PDN&#xD;
      plus cyclosporine [CsA]), should serve as a model for the successful running of early phase&#xD;
      clinical trials for severe and disabling rare diseases of childhood.&#xD;
&#xD;
      The ultimate aim of these trials is to provide evidence-based information about the clinical&#xD;
      utility of drugs in the management of rare paediatric conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 31, 2006</start_date>
  <completion_date type="Actual">November 29, 2015</completion_date>
  <primary_completion_date type="Actual">May 12, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder Status Defined as 20% Improvement in at Least 3 Core Set Variables With no More Than 1 of the Remaining Variables, (Muscle Strength Excluded), Worsened by &gt; 30%.</measure>
    <time_frame>6 months</time_frame>
    <description>The PRINTO Juvenile Dermatomyositis (JDM) core set variables are:&#xD;
muscle strength by the mean of the Childhood Myositis Assessment Scale (CMAS);&#xD;
physician's global assessment of disease activity on a 10 cm Visual Analogue Scale (VAS);&#xD;
global disease activity assessment by the mean of the Disease Activity Index (DAS);&#xD;
parent's/patient's global assessment of overall well-being on a 10 cm VAS;&#xD;
functional ability assessment by the mean of the Childhood Health Assessment Questionnaire (CHAQ)&#xD;
health-related quality of life assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Clinical Remission</measure>
    <time_frame>60 months</time_frame>
    <description>Clinical remission is defined as the status of inactive disease for at least 6 continuous months defined as normal muscle strength (CMAS equal to 52) and physician global assessment of disease activity equal to 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Major Therapeutic Changes</measure>
    <time_frame>60 months</time_frame>
    <description>Time to major therapeutic changes is defined as the addition of CSA or MTX or any other disease-modifying antirheumatic drug (DMARS) in any of the 3 groups or discontinuation of assigned therapy for any reason including adverse events. Retention on treatment was used as main measure of effectiveness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Prednisone, or Equivalent, Discontinuation</measure>
    <time_frame>60 months</time_frame>
    <description>Prednisone or equivalent glucocorticoid discontinuation is defined as the complete discontinuation of glucocorticoids</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Juvenile Dermatomyositis</condition>
  <arm_group>
    <arm_group_label>Methylprednisolone pulse (MPDN)+PDN+CSA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MPDN+PDN+MTX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MPDN= methylprednisolone pulse PDN= prednisone or equivalent MTX= methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MPDN+PDN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MPDN= methylprednisolone PDN= prednisone or equivalent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 MPDN pulse + PDN</intervention_name>
    <description>3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.</description>
    <arm_group_label>MPDN+PDN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 MPDN pulse + PDN + CSA</intervention_name>
    <description>3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses</description>
    <arm_group_label>Methylprednisolone pulse (MPDN)+PDN+CSA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 MPDN pulse + PDN + MTX</intervention_name>
    <description>3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.</description>
    <arm_group_label>MPDN+PDN+MTX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria. Each patient must meet all the following criteria in order to&#xD;
        participate in this trial:&#xD;
&#xD;
          1. Newly diagnosed and untreated children (only treatment with 1 NSAID is allowed and/or&#xD;
             prednisone &gt;1 mg/kg/day for no more than 1 month from diagnosis) with probable or&#xD;
             definite diagnosis of JDM according to published (12;13). If a muscle biopsy will be&#xD;
             performed (optional) it will be read by the pathologists of the participating centres&#xD;
             (light and immunofluorescence). Slides of paraffin-embedded sections from all patients&#xD;
             will be re-viewed by a blinded myopathologist at PRINTO.&#xD;
&#xD;
          2. Age at enrolment ≤ 18 years.&#xD;
&#xD;
          3. Female of child-bearing potential must have a negative pregnancy test at the beginning&#xD;
             of the trial, and then every 3 months. If sexually active, they must agree to use&#xD;
             adequate contraception, throughout study participation, and must have no intention of&#xD;
             conceiving during the course of the study. Post-pubertal males must have no plans to&#xD;
             father a child during the study and agree to use adequate birth control methods if&#xD;
             sexually active.&#xD;
&#xD;
          4. Ability to comply with the entire study procedures, ability to communicate&#xD;
             meaningfully with the investigational staff, competence to give written informed&#xD;
             consent; to be applied to the parents and/or patients, as appropriate&#xD;
&#xD;
          5. Duly executed, written, informed consent obtained from the parents/patient.&#xD;
&#xD;
        Exclusion Criteria. Any of the following will exclude a patient from this trial:&#xD;
&#xD;
          1. Neutrophil count &lt;1,500/mm3 and/or platelet count &lt;50,000/mm3&#xD;
&#xD;
          2. Demonstration of cutaneous or gastrointestinal ulceration of JDM related pulmonary&#xD;
             disease or cardiomyopathy at the time of diagnosis.&#xD;
&#xD;
          3. History of poor compliance.&#xD;
&#xD;
          4. Evidence of current use of alcohol or illicit drugs abuse.&#xD;
&#xD;
          5. Live vaccines not allowed during the entire duration of the trial.&#xD;
&#xD;
        Dropout Criteria. Patients will be considered &quot;treatment failures&quot;, and dropped from the&#xD;
        trial but included in efficacy analysis, if any of the following will occur during the&#xD;
        active period of the trial.&#xD;
&#xD;
          1. Non compliance with study medication administration&#xD;
&#xD;
          2. Enrolment in other therapeutic trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolino Ruperto, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Giannina Gaslini _ PRINTO Senior Scientist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Martini, MD, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Giannina Gaslini_PRINTO Chairman</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genoa</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.printo.it</url>
    <description>Web site of the international network who is conducting the trial</description>
  </link>
  <link>
    <url>http://www.pediatric-rheumatology.printo.it</url>
    <description>Web site for families in 50 different languages with information about the pediatric rheumatic diseases</description>
  </link>
  <reference>
    <citation>Miller LC, Sisson BA, Tucker LB, DeNardo BA, Schaller JG. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum. 1992 Oct;35(10):1143-9.</citation>
    <PMID>1418005</PMID>
  </reference>
  <reference>
    <citation>Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol. 2000;19(2):138-41.</citation>
    <PMID>10791626</PMID>
  </reference>
  <reference>
    <citation>Heckmatt J, Hasson N, Saunders C, Thompson N, Peters AM, Cambridge G, Rose M, Hyde SA, Dubowitz V. Cyclosporin in juvenile dermatomyositis. Lancet. 1989 May 13;1(8646):1063-6.</citation>
    <PMID>2566009</PMID>
  </reference>
  <reference>
    <citation>Pistoia V, Buoncompagni A, Scribanis R, Fasce L, Alpigiani G, Cordone G, Ferrarini M, Borrone C, Cottafava F. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study. Clin Exp Rheumatol. 1993 Mar-Apr;11(2):203-8.</citation>
    <PMID>8508564</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 9, 2006</study_first_submitted>
  <study_first_submitted_qc>May 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2006</study_first_posted>
  <results_first_submitted>April 6, 2017</results_first_submitted>
  <results_first_submitted_qc>February 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2021</results_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Giannina Gaslini</investigator_affiliation>
    <investigator_full_name>Nicolino Ruperto, MD, MPH</investigator_full_name>
    <investigator_title>Senior Scientist of PRINTO</investigator_title>
  </responsible_party>
  <keyword>Juvenile dermatomyositis</keyword>
  <keyword>randomised actively controlled clinical trial</keyword>
  <keyword>prednisone</keyword>
  <keyword>cyclosporine</keyword>
  <keyword>methotrexate</keyword>
  <keyword>effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatomyositis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be provided upon request to the Paediatric Rheumatology InterNational Trials Organisation (PRINTO) network as per its bylaws</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available upon request</ipd_time_frame>
    <ipd_access_criteria>Request to the Paediatric Rheumatology International Trials Organisation (PRINTO) international coordinating centre: PRINTO@gaslini.org</ipd_access_criteria>
    <ipd_url>https://www.PRINTO.it/</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Methylprednisolone Pulse+Prednisone</title>
          <description>Group 1 received 3 pulses of methylprednisolone and has been randomized to prednisone or equivalent</description>
        </group>
        <group group_id="P2">
          <title>Methylprednisolone Pulse+Prednisone+Cyclosporine A</title>
          <description>Group 2 received 3 pulses of methylprednisolone and has been randomized to prednisone or equivalent plus cyclosporine A</description>
        </group>
        <group group_id="P3">
          <title>Methylprednisolone Pulses+Prednisone+Methotrexate</title>
          <description>Group 3 received 3 pulses of methylprednisolone and has been randomized to prednisone or equivalent plus methotrexate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MPDN+PDN</title>
          <description>MPDN+PDN MPDN= methylprednisolone PDN= prednisone or equivalent&#xD;
3 MPDN pulse + PDN: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.</description>
        </group>
        <group group_id="B2">
          <title>MPDN+PDN+CSA</title>
          <description>MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A&#xD;
3 MPDN pulse + PDN + CSA: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses</description>
        </group>
        <group group_id="B3">
          <title>MPDN+PDN+MTX</title>
          <description>MPDN= methylprednisolone pulse PDN= prednisone or equivalent MTX= methotrexate&#xD;
3 MPDN pulse + PDN + MTX: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="46"/>
            <count group_id="B4" value="139"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>For age it is intended age at first observation</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" lower_limit="5.1" upper_limit="10.1"/>
                    <measurement group_id="B2" value="8.9" lower_limit="5.1" upper_limit="12.4"/>
                    <measurement group_id="B3" value="7.1" lower_limit="4.3" upper_limit="10.4"/>
                    <measurement group_id="B4" value="7.5" lower_limit="4.6" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Algeria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Venezuela</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>disease duration</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.6" lower_limit="1.2" upper_limit="5.1"/>
                    <measurement group_id="B2" value="2.7" lower_limit="1.2" upper_limit="6.2"/>
                    <measurement group_id="B3" value="2.8" lower_limit="1.9" upper_limit="5.0"/>
                    <measurement group_id="B4" value="2.8" lower_limit="1.3" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Responder Status Defined as 20% Improvement in at Least 3 Core Set Variables With no More Than 1 of the Remaining Variables, (Muscle Strength Excluded), Worsened by &gt; 30%.</title>
        <description>The PRINTO Juvenile Dermatomyositis (JDM) core set variables are:&#xD;
muscle strength by the mean of the Childhood Myositis Assessment Scale (CMAS);&#xD;
physician's global assessment of disease activity on a 10 cm Visual Analogue Scale (VAS);&#xD;
global disease activity assessment by the mean of the Disease Activity Index (DAS);&#xD;
parent's/patient's global assessment of overall well-being on a 10 cm VAS;&#xD;
functional ability assessment by the mean of the Childhood Health Assessment Questionnaire (CHAQ)&#xD;
health-related quality of life assessment.</description>
        <time_frame>6 months</time_frame>
        <population>Comparison between group 2 (PDN+CSA) and 3 (PDN+MTX) combined versus group 1 (PDN)</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (MPDN+PDN)</title>
            <description>MPDN+PDN MPDN= methylprednisolone PDN= prednisone or equivalent&#xD;
3 MPDN pulse + PDN: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (MPDN+PDN+CSA)</title>
            <description>MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A&#xD;
3 MPDN pulse + PDN + CSA: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (MPDN+PDN+MTX)</title>
            <description>MPDN= methylprednisolone pulse PDN= prednisone or equivalent MTX= methotrexate&#xD;
3 MPDN pulse + PDN + MTX: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Status Defined as 20% Improvement in at Least 3 Core Set Variables With no More Than 1 of the Remaining Variables, (Muscle Strength Excluded), Worsened by &gt; 30%.</title>
          <description>The PRINTO Juvenile Dermatomyositis (JDM) core set variables are:&#xD;
muscle strength by the mean of the Childhood Myositis Assessment Scale (CMAS);&#xD;
physician's global assessment of disease activity on a 10 cm Visual Analogue Scale (VAS);&#xD;
global disease activity assessment by the mean of the Disease Activity Index (DAS);&#xD;
parent's/patient's global assessment of overall well-being on a 10 cm VAS;&#xD;
functional ability assessment by the mean of the Childhood Health Assessment Questionnaire (CHAQ)&#xD;
health-related quality of life assessment.</description>
          <population>Comparison between group 2 (PDN+CSA) and 3 (PDN+MTX) combined versus group 1 (PDN)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We calculated that a sample size of 40 patients would be needed in each study group (total 120 patients) to have 80% power for comparison of combination treatments (prednisone plus methotrexate or prednisone plus ciclosporin) with the reference treatment (prednisone alone).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0228</p_value>
            <p_value_desc>For multiple hypothesis testing, we used Bonferroni's correction (with n=3 posterior comparisons).</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>To assess proportions we used the χ² test or Fisher's exact test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Clinical Remission</title>
        <description>Clinical remission is defined as the status of inactive disease for at least 6 continuous months defined as normal muscle strength (CMAS equal to 52) and physician global assessment of disease activity equal to 0.</description>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (MPDN+PDN)</title>
            <description>MPDN+PDN MPDN= methylprednisolone PDN= prednisone or equivalent&#xD;
3 MPDN pulse + PDN: 3 methylprednisolone pulses (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (MPDN+PDN+CSA)</title>
            <description>MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A&#xD;
3 MPDN pulse + PDN + CSA: 3 methylprednisolone pulses (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (MPDN+PDN+MTX)</title>
            <description>MPDN= methylprednisolone pulse PDN= prednisone or equivalent MTX= methotrexate&#xD;
3 MPDN pulse + PDN + MTX: 3 methylprednisolone pulses (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Clinical Remission</title>
          <description>Clinical remission is defined as the status of inactive disease for at least 6 continuous months defined as normal muscle strength (CMAS equal to 52) and physician global assessment of disease activity equal to 0.</description>
          <units>events per 1000 persons-time</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.99" lower_limit="3.00" upper_limit="11.98"/>
                    <measurement group_id="O2" value="4.95" lower_limit="2.36" upper_limit="10.38"/>
                    <measurement group_id="O3" value="13.39" lower_limit="8.07" upper_limit="22.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We used the Kaplan-Meier method to produce survival curves (groups 1 and 2 versus group 3) and compared them with the Log-Rank test. We judged a p value less than 0·05 significant. We reported in the table the incidence rates with 95% confidence intervals of the 3 groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Log Rank</method>
            <param_type>Relative risk</param_type>
            <param_value>2.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
            <estimate_desc>RR related to prednisone plus methotrexate arm (group 3) versus prednisone alone (group 1) and prednisone plus ciclosporin (group 2).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Major Therapeutic Changes</title>
        <description>Time to major therapeutic changes is defined as the addition of CSA or MTX or any other disease-modifying antirheumatic drug (DMARS) in any of the 3 groups or discontinuation of assigned therapy for any reason including adverse events. Retention on treatment was used as main measure of effectiveness.</description>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (MPDN+PDN)</title>
            <description>MPDN+PDN MPDN= methylprednisolone PDN= prednisone or equivalent&#xD;
3 MPDN pulse + PDN: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (MPDN+PDN+CSA)</title>
            <description>MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A&#xD;
3 MPDN pulse + PDN + CSA: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (MPDN+PDN+MTX)</title>
            <description>MPDN= methylprednisolone pulse PDN= prednisone or equivalent MTX= methotrexate&#xD;
3 MPDN pulse + PDN + MTX: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Major Therapeutic Changes</title>
          <description>Time to major therapeutic changes is defined as the addition of CSA or MTX or any other disease-modifying antirheumatic drug (DMARS) in any of the 3 groups or discontinuation of assigned therapy for any reason including adverse events. Retention on treatment was used as main measure of effectiveness.</description>
          <units>events per 1000 persons-time</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.52" lower_limit="21.34" upper_limit="43.65"/>
                    <measurement group_id="O2" value="17.52" lower_limit="11.31" upper_limit="27.16"/>
                    <measurement group_id="O3" value="13.92" lower_limit="8.65" upper_limit="22.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We used the Kaplan-Meier method to produce survival curves (group 1 versus groups 2 and 3) and compared them with the Log-Rank test. We judged a p value less than 0·05 significant. We reported in the table the incidence rates with 95% confidence intervals of the 3 groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Log Rank</method>
            <param_type>Relative risk</param_type>
            <param_value>1.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>3.15</ci_upper_limit>
            <estimate_desc>RR related to prednisone alone (group 1) versus prednisone plus ciclosporin (group 2) and prednisone plus methotrexate arm (group 3).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Prednisone, or Equivalent, Discontinuation</title>
        <description>Prednisone or equivalent glucocorticoid discontinuation is defined as the complete discontinuation of glucocorticoids</description>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 (MPDN+PDN)</title>
            <description>MPDN+PDN MPDN= methylprednisolone PDN= prednisone or equivalent&#xD;
3 MPDN pulse + PDN: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.</description>
          </group>
          <group group_id="O2">
            <title>Group 2 (MPDN+PDN+CSA)</title>
            <description>MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A&#xD;
3 MPDN pulse + PDN + CSA: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses</description>
          </group>
          <group group_id="O3">
            <title>Group 3 (MPDN+PDN+MTX)</title>
            <description>MPDN= methylprednisolone pulse PDN= prednisone or equivalent MTX= methotrexate&#xD;
3 MPDN pulse + PDN + MTX: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Prednisone, or Equivalent, Discontinuation</title>
          <description>Prednisone or equivalent glucocorticoid discontinuation is defined as the complete discontinuation of glucocorticoids</description>
          <units>events per 1000 persons-time</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.91" lower_limit="10.15" upper_limit="24.94"/>
                    <measurement group_id="O2" value="27.82" lower_limit="19.56" upper_limit="39.55"/>
                    <measurement group_id="O3" value="24.42" lower_limit="16.50" upper_limit="36.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We used the Kaplan-Meier method to produce survival curves (groups 2 and 3 versus group 1) and compared them with the Log-Rank test. We judged a p value less than 0·05 significant. We reported in the table the incidence rates with 95% confidence intervals of the 3 groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Log Rank</method>
            <param_type>Relative risk</param_type>
            <param_value>1.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.24</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
            <estimate_desc>RR related to prednisone+methotrexate arm or prednisone+ciclosporin versus prednisone alone.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We used the Kaplan-Meier method to produce survival curves (groups 1 versus groups 2 and 3) and compared them with the Log-Rank test. We judged a p value less than 0·05 significant. We reported in the table the incidence rates with 95% confidence intervals of the 3 groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Log Rank</method>
            <param_type>Relative risk</param_type>
            <param_value>1.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.24</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
            <estimate_desc>RR related to prednisone alone (group 1) versus prednisone plus ciclosporin (group 2) and prednisone plus methotrexate arm (group 3).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MPDN+PDN</title>
          <description>MPDN+PDN MPDN= methylprednisolone PDN= prednisone or equivalent&#xD;
3 MPDN pulse + PDN: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.</description>
        </group>
        <group group_id="E2">
          <title>MPDN+PDN+CSA</title>
          <description>MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A&#xD;
3 MPDN pulse + PDN + CSA: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses</description>
        </group>
        <group group_id="E3">
          <title>MPDN+PDN+MTX</title>
          <description>MPDN= methylprednisolone pulse PDN= prednisone or equivalent MTX= methotrexate&#xD;
3 MPDN pulse + PDN + MTX: 3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Posterior reversible encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Dermo-hypodermitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushing syndrome</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection and infestations</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increases in serum creatinine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Metabolic disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertrichosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hirsutism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nicolino Ruperto</name_or_title>
      <organization>IRCCS Istituto Giannina Gaslini</organization>
      <phone>+39-010-382854</phone>
      <email>nicolaruperto@gaslini.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

